Research News
![[title]](http://alsn.mda.org/files/alsn/imagecache/175xFrontFeature/Research%20Grants%20lead%20art.jpg)
January 06, 2010
In December 2009, MDA awarded $21 million in new research grants for neuromuscular disease research.
MDA's Scientific Advisory Committee (SAC) and Medical Advisory Committee (MAC) meet each fall
January 01, 2010
The items in this article address research in ALS as of December 31, 2009, on these topics: Gulf War connection, smoking, serum lipids, arimoclomol study, microRNA 206 potential.
Why wait for the
![[title]](http://alsn.mda.org/files/alsn/imagecache/175xFrontFeature/Berlin%20main%20.jpg)
January 01, 2010
Although electronic communications allow rapid transmission of information among laboratories around the world, face-to-face meetings still play an important role in research. Many new collaborations
![[title]](http://quest.mda.org/sites/default/files/imagecache/mda_org_frontpage100x75/DNA%20LeadArt.JPG)
December 17, 2009
Development of a promising experimental medication to treat Friedreich's ataxia (FA) is proceeding, with help from a $731,534 grant MDA awarded to Repligen Corp. of Waltham, Mass., this month (
December 16, 2009
A molecule called microRNA 206, produced by muscle fibers after an injury to nerve cells, helps rebuild crucial nerve-muscle communications, say scientists at the University of Texas Southwestern
December 09, 2009
New findings suggest a possible link between dust-dwelling bacterial toxins and an elevated incidence of ALS (amyotrophic lateral sclerosis) in Gulf War veterans.
The study blames cyanobacteria,
December 09, 2009
ALS researchers from around the world gathered in Berlin, Germany, Dec. 8-10, to report on and discuss the latest research advances in this disease.
Daily updates from the symposium are available
December 08, 2009
A clinical trial of an experimental drug for ALS -- halted almost two years ago due to safety concerns –- has been given the green light to continue with a revised protocol, says CytRx Corp. of Los
![[title]](http://quest.mda.org/sites/default/files/imagecache/mda_org_frontpage100x75/DMD%20boy%2C%20clinic.jpg)
December 03, 2009
A comprehensive set of clinical care recommendations for the diagnosis and management of Duchenne muscular dystrophy (DMD) is now available to medical professionals and families.
The complete
November 17, 2009
A new analysis says that smoking, already suspected of being a risk factor for amyotrophic lateral sclerosis (ALS), definitely is one. (See the 2004 story, Smoking Is Likely ALS Risk Factor.)
November 06, 2009
An Italian trial to test the effects of lithium carbonate in amyotrophic lateral sclerosis (ALS) has ended before its originally scheduled completion date because of an unusually high number of
November 01, 2009
Several recent studies by MDA-supported researchers have furthered interest in the possible benefits of targeting muscle instead of nerve tissue as a means to slow loss of strength in people withALS
November 01, 2009
Why wait for the next ALS Newsmagazine? Receive monthly e-mail summaries of breaking research news directly in your inbox. Go to quest.mda.org and click "Quest News Sign Up."
Trial of SOD1 blocker
October 30, 2009
An all-day "think tank" to consider priorities for amyotrophic lateral sclerosis (ALS) research based on the latest information was conducted with ten of the leading scientists and clinicians in
October 29, 2009
A compound known as "activated protein C" (APC) that is already in use to treat severe bloodstream infections also may have benefit in ALS, according to a recently published report.
APC reduced
![[title]](http://quest.mda.org/sites/default/files/imagecache/mda_org_frontpage100x75/exon%20skip%20LeadArt.jpg)
October 28, 2009
The first human trial in the United States of a treatment strategy known as "exon skipping" for Duchenne muscular dystrophy (DMD) is scheduled to begin in March 2010 at Nationwide Children's Hospital
October 27, 2009
Exon skipping is an experimental strategy that could help some boys and young men with Duchenne muscular dystrophy produce dystrophin, the muscle protein that's missing in this disease.
The first
October 19, 2009
A phase 1 clinical trial of the experimental drug ISIS-SOD1-Rx in patients with the SOD1-related type of familial (inherited) amyotrophic lateral sclerosis (ALS) is expected to begin before the
October 18, 2009
A Webcast is now available of the fourth annual research symposium held as part of the ALS TDI Leadership Summit 2009 on Oct. 5. The symposium was conducted at the MDA-supported ALS Therapy
October 10, 2009
A new test panel that can detect “up to 35 percent” of the genetic flaws that can cause familial (inherited) ALS has been announced by Athena Diagnostics of Worcester, Mass.
Athena is a commercial
October 10, 2009
The federal government has released preliminary details about the new National ALS Registry, which will be launched in late 2010. A list of frequently asked questions (FAQs) about ALS and the
October 08, 2009
Mice carrying a mutation in the gene for the TDP43 protein that's known to cause amyotrophic lateral sclerosis (ALS) in humans have been developed by MDA-supported scientists at Washington
September 29, 2009
New research supports strategies that augment a natural process in the nervous system called autophagy – a cellular cleanup and garbage-disposal system — as a possible therapeutic avenue in
September 28, 2009
Scientists at the Scripps Research Institute in La Jolla, Calif., and the Repligen Corporation in Waltham, Mass., have identified the precise biochemical brake that limits production of a needed
September 24, 2009
The investigators on a study of lithium carbonate in amyotrophic lateral sclerosis (ALS), funded by the National Institutes of Health, the ALS Association and the ALS Society of Canada, announced
Pages
Connect with MDA
Muscular Dystrophy Association — USA
National Headquarters
3300 E. Sunrise Drive
Tucson, AZ 85718
(800) 572-1717
©2013, Muscular Dystrophy Association Inc. All rights reserved.
